AFX 221

Drug Profile

AFX 221

Alternative Names: AFX-221; Molindone - Afecta Pharmaceuticals; NGI-221

Latest Information Update: 24 Jun 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Afecta Pharmaceuticals
  • Class Antipsychotics; Indoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase Unknown Attention-deficit hyperactivity disorder; Gilles de la Tourette's syndrome

Most Recent Events

  • 20 Jun 2008 Investigation in Attention-deficit hyperactivity disorder in USA (PO)
  • 20 Jun 2008 Investigation in Gilles de la Tourette's syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top